Perifer arter hastalığı olan ve olmayan hastalarda endocan seviyesi karşılaştırılması
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Selçuk Üniversitesi, Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Periferik arter hastalığı (PAH),abdominal aort ve aortun bifurkasyon seviyesinin distalindeki arterlerde tıkanıklık ile kendini gösteren, ilerleyici aterosklerozisin eşlik ettiği bir hastalıktır. Periferik arter hastalığı, görülme sıklığı giderek artan önemli bir sağlık sorunudur Dünyada 200 milyondan fazla insanın PAH'tan etkilendiği tahmin edilmektedir. Periferik arter hastalığı asemptomatik olabildiği gibi yürümekle artan istirahatla azalan intermittan kladikasyo olarak bilinen bacak ağrısı şeklinde semptom verir. Önceleri yürümekle ortaya çıkan bu ağrı (intermittan kladikasyo) ilerleyen dönemde istirahatte de görülür hale gelmektedir. Hastalarını bazıları ülserasyon veya gangrenle de başvururlar. Dünyada aterosklerotık kardiyovasküler morbiditeye neden olan üçüncü nedendir. Endotel hücresine özgü molekül 1(Endocan), vasküler endotel hücreleri tarafından salgılananan, çözünebilen 50 kda ağırlığında bir dermatan sülfat proteoglikandır. Endocan, endotel disfonksiyonunun yeni bir biyolojik belirtecidir. Kronik böbrek hastalıklarında, renal transplant rejeksiyonlarında, hipertansiyonda ve tümör progresyonunda endocan seviyelerinin artış gösterdiği görülmüştür. Endotelyal disfonksiyon aterosklerotik hastalıkların çoğu zaman ilk bulgusudur. Biz bu çalışmamızda; Perifer arter hastalığı olan hastalarda ve sağlıklı kişilerde serum Endocan düzeylerini ölçerek, periferik arter hastalığını non-invazif, erken bir biyokimyasal öngördürücü olarak değerini araştırmak ve literatüre katkı sağlamayı amaçladık. Periferik arter hastalığının varlığına göre 110 gönüllü 2 gruba ayrıldı.110 hastanın 56 (%50,9) sinde perifer arter hastalığı olduğu görüldü. Endocan seviyesi PAH olan grupta PAH olmayan gruba göre belirgin olarak yüksek olmasına rağmen bu yükseklik istatistiksel olarak anlamlılığa ulaşmadı(sırasıyla 218,76 pg/ml ± 166,95 pg/ml ve 170,48 pg/ml± 90,06 pg/ml, p=0.063). Ayrıca iki grup arasında HT, DM, KAH, HL oranları benzerdi. (p=0,84). Serum kreatinin değeri PAH grubunda daha yüksekti(p=0,003). Serum HDL değeri PAH grubunda daha düşük olarak saptandı(p < 0.00). Hemoglobin değeri PAH grubunda daha düşükken(p=0.00) nötrofil sayısı PAH grununda daha yüksek saptandı(p=0.022). Sistolik ve diyastolik kan basıncı her iki grupta benzerdi(p=0,88). Sonuç olarak; ENDOCAN seviyesinin, PAH'ın non-invazif, erken bir biyokimyasal öngördürücü olarak istatistiksel olarak anlamlı olmasa da yüksek olduğunu gördük. Bunlara ilaveten; hasta sayısının az olmasından dolayı kesin bir neticeye varmamız mümkün görünmemekte; yine de bu önemli neticeler ışığında daha fazla hasta sayılarıyla daha büyük çalışmalara ihtiyaç vardır.
Peripheral arterial disease (PAD) is a disease accompanied by progressive atherosclerosis manifested by occlusion of the distal arteries of the abdominal aorta and aortic bifurcation level. Peripheral artery disease is an important health problem with increasing frequency It is estimated that more than 200 million people in the world are affected by PAH. Peripheral arterial disease may be asymptomatic or as a leg pain, which is known as intermittent kladikasyon. This pain (claudication intermittens), which was seen by walking in the past, is also seen in the resting period. Some of the patients also present with ulceration or gangrene Atherosclerotic is the third cause of cardiovascular morbidity in the world Endothelial cell-specific molecule 1 (endocan) is a dermatan sulfate proteoglycan, soluble 50 kda, secreted by vascular endothelial cells. Endocan is a new biological marker of endothelial dysfunction. Endocan levels have been observed to increase in chronic renal diseases, renal transplant rejection, hypertension and tumor progression. Endothelial dysfunction is often the first finding of atherosclerotic diseases. In this study; We aimed to investigate the value of peripheral arterial disease as a non-invasive, early biochemical predictor by measuring serum endocan levels in patients with peripheral artery disease and healthy individuals and to contribute to the literature. 110 volunteers were divided into 2 groups according to the presence of peripheral artery disease. Of the 110 patients, 56 (50.9%) had peripheral artery disease. Although the Endocan level was significantly higher in the PAH group than in the non-PAH group, this elevation did not reach statistical significance (respectively; 218,76 pg/ml ± 166,95 pg/ml and 170,48 pg7ml ± 90,06 pg/ml p= 0.063,). In addition, HT, DM, CAD, HL ratios were similar between the two groups. (p = 0.84), Serum creatinine value was higher in PAH group. (P = 0.003). Serum HDL levels were lower in the PAH group. p <0.00) left ventricular ejection fraction (p = 0.142), systolic and diastolic blood pressure (p = 0.88) were similar. As a result;We found that ENDOCAN level was high, although not statistically significant, as a non-invasive, early biochemical predictor of PAH. In addition; we do not seem to be able to conclude because of the small number of patients; however, larger studies with more patient numbers are needed in the light of these important results. Keywords: Peripheral artery disease, Endocan,
Peripheral arterial disease (PAD) is a disease accompanied by progressive atherosclerosis manifested by occlusion of the distal arteries of the abdominal aorta and aortic bifurcation level. Peripheral artery disease is an important health problem with increasing frequency It is estimated that more than 200 million people in the world are affected by PAH. Peripheral arterial disease may be asymptomatic or as a leg pain, which is known as intermittent kladikasyon. This pain (claudication intermittens), which was seen by walking in the past, is also seen in the resting period. Some of the patients also present with ulceration or gangrene Atherosclerotic is the third cause of cardiovascular morbidity in the world Endothelial cell-specific molecule 1 (endocan) is a dermatan sulfate proteoglycan, soluble 50 kda, secreted by vascular endothelial cells. Endocan is a new biological marker of endothelial dysfunction. Endocan levels have been observed to increase in chronic renal diseases, renal transplant rejection, hypertension and tumor progression. Endothelial dysfunction is often the first finding of atherosclerotic diseases. In this study; We aimed to investigate the value of peripheral arterial disease as a non-invasive, early biochemical predictor by measuring serum endocan levels in patients with peripheral artery disease and healthy individuals and to contribute to the literature. 110 volunteers were divided into 2 groups according to the presence of peripheral artery disease. Of the 110 patients, 56 (50.9%) had peripheral artery disease. Although the Endocan level was significantly higher in the PAH group than in the non-PAH group, this elevation did not reach statistical significance (respectively; 218,76 pg/ml ± 166,95 pg/ml and 170,48 pg7ml ± 90,06 pg/ml p= 0.063,). In addition, HT, DM, CAD, HL ratios were similar between the two groups. (p = 0.84), Serum creatinine value was higher in PAH group. (P = 0.003). Serum HDL levels were lower in the PAH group. p <0.00) left ventricular ejection fraction (p = 0.142), systolic and diastolic blood pressure (p = 0.88) were similar. As a result;We found that ENDOCAN level was high, although not statistically significant, as a non-invasive, early biochemical predictor of PAH. In addition; we do not seem to be able to conclude because of the small number of patients; however, larger studies with more patient numbers are needed in the light of these important results. Keywords: Peripheral artery disease, Endocan,
Açıklama
Anahtar Kelimeler
Perifer Arter Hastalığı, Endocan, Peripheral Artery Disease
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Aydoğan, C. (2020). Perifer arter hastalığı olan ve olmayan hastalarda endocan seviyesi karşılaştırılması. (Uzmanlık Tezi). Selçuk Üniversitesi, Tıp Fakültesi, Konya.